Rubraca
Payments companies reported to CMS as associated with Rubraca. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Rubraca, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Rubraca
These are the largest totals companies reported as associated with Rubraca. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Eleni Efstathiou | Houston, TX | Medical Oncology | $18,012.60 |
| Alan Bryce | Scottsdale, AZ | Hematology & Oncology | $9,541.71 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $9,479.54 |
| Sharad Ghamande | Augusta, GA | Gynecologic Oncology | $8,453.27 |
| Thomas Herzog | Cincinnati, OH | Gynecologic Oncology | $6,073.99 |
| David Morris | Hendersonville, TN | Urology | $4,314.82 |
| Aaron Berger | Chicago Ridge, IL | Urology | $2,229.04 |
| Andrew Hahn | Houston, TX | Internal Medicine | $1,460.84 |
| Ghasoub Harb | Davenport, IA | Urology | $240.52 |
| Richard Lewis | Jacksonville, FL | Urology | $240.52 |
Prescribed Rubraca?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.